000			01621nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aPaediatric Formulation: Design and Development
546			_aEnglish[eng]
650			_adasatinib||Duchenne muscular dystrophy||cyclodextrin inclusion complex||phase solubility studies||paediatric age||liquid formulation||tumorspheres||retinoblastoma||topotecan||penetration||confocal microscopy||poorly water soluble drug||solubility enhancement||grinding||spray congealing||neglected tropical diseases||polymorph||Norvir®||ritonavir||poorly soluble compound||pediatric||palatability assessment||bioavailability||flavor profile||Interleukin-1||anakinra||canakinumab||innovative biotechnologies||autoinflammatory disease||Kawasaki disease||systemic juvenile idiopathic arthritis||personalized medicine||child||pediatrics||neonates||formulation||product development||formulation development||oral||parenteral||topical||inhaled||intra nasal||biopharmaceutics||administration||excipient||NICU||device||medication error||dosage form||modified release||drug delivery||paediatric formulation development||paediatric dosage forms||chronic myeloid leukemia||tyrosine kinase inhibitors||pediatric age||imatinib||nilotinb||ponatinib||Orodispersible formulation||pyrazinamide||pediatric drug delivery||tuberculosis||design of experiments||children||edible films||development||design||paediatric||age-related||palatable||taste-masking||acceptable
700			_aDenora, Nunzio||Lopalco, Antonio
856			_uhttps://mdpi.com/books/pdfview/book/3873
942			_cEB
999			_c29907 _d29907